Literature DB >> 20731578

The unique issues of outpatient parenteral antimicrobial therapy in children and adolescents.

Mobeen H Rathore1.   

Abstract

The decision to discharge a hospitalized child or adolescent to receive outpatient parenteral antimicrobial therapy (OPAT) is based on criteria very different from those concerning adults. Clinical studies of pediatric OPAT are sparse, as are pharmacokinetic data for antimicrobial agents in children. Other issues unique to children are requirements for special nursing and intravenous infusion skills, as well as the increase of complications. The psychological disadvantage of hospitalization in children, compared with adults, is great, and both populations are equally vulnerable to nosocomial infection, increasingly augmented by multidrug-resistant organisms. Although the relatively few clinical studies involving OPAT in children attest to its efficacy and safety, well-designed prospective trials and comprehensive cost-benefit analyses are still needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731578     DOI: 10.1086/653521

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Economic Burden of Home Antimicrobial Therapy: OPAT Versus Oral Therapy.

Authors:  Nathan M Krah; Tyler Bardsley; Richard Nelson; Lawanda Esquibel; Mark Crosby; Carrie L Byington; Andrew T Pavia; Adam L Hersh
Journal:  Hosp Pediatr       Date:  2019-04

2.  Treatment-Related Complications in Children Hospitalized With Disseminated Lyme Disease.

Authors:  Christine Chang; Kristen A Feemster; Susan Coffin; Lori K Handy
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

3.  Adverse Events in Pediatric Patients Receiving Long-Term Outpatient Antimicrobials.

Authors:  Scott C Olson; Sherilyn Smith; Scott J Weissman; Matthew P Kronman
Journal:  J Pediatric Infect Dis Soc       Date:  2014-04-30       Impact factor: 3.164

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.